Thermo Fisher Q2 Revenue Reaches $11.99B, Adjusted EPS Hits $6.03, and Guidance Is Raised
TMO sits 35% above its 52-week low of $405.15.
Summary
Thermo Fisher Scientific posted Q2 2026 revenue of $11.99B (+10% YoY) and adjusted EPS of $6.03 (+13% YoY), with 5% organic growth. A microbiology divestiture and $1B in buybacks were also announced.
Key Events · Earnings and Guidance · TMO
-
Q2 Revenue and Earnings Beat
Revenue grew 10% to $11.99B, including 5% organic growth. GAAP diluted EPS rose 9% to $4.68, while adjusted EPS advanced 13% to $6.03.
-
Margin Expansion
Driven by operating leverage and cost discipline, adjusted operating margin expanded to 22.8% from 21.9% a year ago.
-
Capital Deployment
The company announced the divestiture of its microbiology business and repurchased $1.0 billion of stock during the quarter.
-
Updated Guidance Expected
Updated 2026 financial guidance will be provided during the earnings call; a material deviation from consensus could impact the stock.
Analysis · TMO · Industrial Applications And Services
A strong second quarter saw revenue climb 10% to $11.99 billion and adjusted EPS jump 13% to $6.03, both comfortably ahead of typical expectations. Organic growth of 5% points to a broad-based demand recovery across end markets. The quarter also featured a microbiology divestiture and $1 billion in stock repurchases, underscoring disciplined capital deployment. Updated 2026 guidance will be discussed on the earnings call, and any upward revision could move the stock.
At the time of this filing, TMO was trading at $547.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $195.6B. The 52-week trading range was $405.15 to $643.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.